Fig. 2.
SMAPs (DBK-1154 or DBK-1160) treatments reduce Aβ generation in N2a/APP cells. a LDH assay in N2a/APP cells treated with increasing doses of DBK-1154 or DBK-1160 (0, 0.1, 1, 5, and 10 μM) at 24 h. b PP2A activity assay in N2a/APP cells treated with different doses of DBK-1154 or DBK-1160 (0, 0.1, 1, and 5 μM) at 24 h. c, d ELISA assay of intracellular Aβ40 and Aβ42 levels after treatment with SMAPs at different dosages (0, 0.1, 1, and 5 μM) for 24 h. e Western blots for APP, sAPPβ, pT668APP, BACE1, and PS1 in N2a/APP cells treated with DBK-1154 or DBK-1160 (5 μM) for 24 h. f–j Quantification of the relative protein expression level (APP, sAPPβ, pT668APP, BACE1, and PS1) after normalization to the GAPDH signal. k IP blots for BACE1 interacted with APP in N2a/APP cells treated with DBK-1154 or DBK-1160 (5 μM) for 24 h. l Quantitative analysis of the IP blots. m BACE activity assay in N2a/APP cells treated with DBK-1154 or DBK-1160 (5 μM) at 24 h. Data represent mean ± SD, n = 3. *P < 0.05, **P < 0.01, ***P < 0.001 versus control. 1160: DBK-1160, 1154: DBK-1154